Table 2 Ranking different potential designs for ivermectin-based tools
From: Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway
Regimen | Efficacy | Safety | Acceptability | Compliance | Programmatic difficulty | R&D costs | Implementation costs |
|---|---|---|---|---|---|---|---|
High dose, single encounter | To be assessed | To be assessed | + | +++ | + | + | Similar to ACT MDA |
Existing dose, multiple encounters | To be assessed | + | +++ | + | +++ | + | Similar to SMC |
Novel long-lasting formulation, single encounter | To be assessed | To be assessed | To be assessed | +++ | + | +++ | Similar to SMC but high R&D costs and longer timeframe to availability |